Overview
- The Department of Health and Human Services issued an interim enforcement‑discretion policy on Oct. 28 that tells the FDA not to take action against state‑licensed compounders that make BPC‑157, Epitalon, KPV, MOTS‑c, Semax and TB‑500 when they meet specific conditions.
- The policy requires patient‑specific prescriptions, ingredients from FDA‑registered manufacturers with certificates of analysis, limits on dosage forms, and mandatory reporting of serious adverse events to FDA MedWatch and states.
- FDA scientific staff largely opposed easing access and had limited input in drafting the policy, while an FDA advisory panel that recommended the change in July included several recent appointees with ties to the peptide field.
- Industry and telehealth firms signaled rapid commercial interest after the notice, with analysts projecting a multi‑billion dollar market and some providers already marketing peptide offerings; consumer groups warn the move risks wider exposure to unproven or contaminated products.
- The policy is temporary and will remain in effect only until the FDA completes formal rulemaking; HHS opened a public comment period and said it may revise the approach if safety or quality problems emerge.